Original research

Total Hip Arthroplasty for Developmental Dysplasia of Hip vs Osteoarthritis: A Propensity Matched Pair Analysis

Ahmed Siddiqi, DO, MBA a, *, Peter B. White, DO, MS b, Matthew Sloan, MD, MPH c, Duncan Fox, BS d, Nicolas S. Piuzzi, MD e, Wudbhav N. Sankar, MD f, Neil P. Sheth, MD g

a Orthopedic Surgery Adult Reconstruction Fellow, Cleveland Clinic Foundation, Cleveland, OH, USA
b Orthopedic Surgery Resident, Northwell Health, Plainview Hospital, Plainview, NY, USA
c Orthopedic Surgery Resident, Department of Orthopedic Surgery, University of Pennsylvania, Philadelphia, PA, USA
d Undergraduate student, University of Massachusetts, Boston, MA, USA
e Attending Orthopedic Surgeon, Cleveland Clinic Foundation, Cleveland, OH, USA
f Attending Orthopedic Surgeon, Children’s Hospital for Philadelphia, Department of Orthopedic Surgery, Philadelphia, PA, USA
g Attending Orthopedic Surgeon, University of Pennsylvania, Department of Orthopedic Surgery, Pennsylvania Hospital, Philadelphia, PA, USA

ARTICLE INFO

Article history:
Received 15 August 2019
Received in revised form 24 February 2020
Accepted 24 February 2020
Available online 22 June 2020

Keywords:
Developmental hip disease
Congenital hip disease
DDH
Total hip arthroplasty
THA

ABSTRACT

Background: The purpose of this study was to use the American College of Surgeons National Surgical Quality Improvement Program to compare the perioperative and postoperative outcomes after total hip arthroplasty (THA) for DDH and primary OA via a propensity-matched pair analysis and the valuation of THA between both groups.

Material and Methods: All patients who underwent THA between 2008 and 2016 were identified from National Surgical Quality Improvement Program database via the current procedural terminology (CPT) code. Patients were further identified and stratified based on International Statistical Classification of Diseases and Related Health Problems–9/International Statistical Classification of Diseases and Related Health Problems—10 diagnosis codes for primary OA (n = 115,166) and DDH (n = 603), which included codes for congenital hip dislocation, hip dysplasia, or juvenile osteochondrosis. Demographic variables were used to create 557 propensity-matched pairs.

Results: The DDH group was associated with a significantly longer operative time (120.3 vs 95.9 min), higher postoperative transfusion rate (12% vs 6.6%), and longer hospital length of stay (2.8 vs 2.5 days) compared with the primary OA group (P < .001, P < .001, and P = .002, respectively). There were no statistically significant differences found between the two groups with respect to inpatient complications, discharge disposition (P = .123), readmissions (P = .615), or reoperations (P = .404).

Conclusions: Health policy makers should be cognizant of the higher complexity of THA for DDH when determining whether DDH and primary OA should be in the same bundle. Owing to the limitations of our data set, all the observed associations are likely an underestimate of the true risk posed to patients with severe DDH, as these patients were unable to be stratified in the present analysis.

© 2020 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

In recent years, there has been increasing interest in alternative payment models, such as bundled payments, in total hip arthroplasty (THA) [1]. As bundled payments continue to evolve, recent studies have shown that not all indications for THA belong in the same bundle owing to differences in the patient population and clinical outcomes [2,3]. Consequently, it is important to continue to evaluate other indications for THA to determine optimal bundles [4].

Developmental dysplasia of hip (DDH) is a spectrum of disease that comprises one of the leading causes of secondary degenerative osteoarthritis (OA) [5] and is associated with a variety of pathomorphologies, such as congenital hip dysplasia and pelvic malformation that can distort anatomy leading to a more technically demanding surgery at the time of THA [6,7]. Although some studies have shown satisfactory long-term results [8–10], other studies have suggested higher failure rates [11] or worse clinical outcomes.
When THA is performed for DDH as opposed to primary OA. In fact, in the 1970s, Charnley suggested that THA should be avoided in all patients with congenital dislocation of the hip and inadequate bone stock [13]. However, the majority of available studies are case series [8–12], and to our knowledge, there are no any large registry studies to compare the outcomes of THA for DDH with primary OA.

Therefore, the purpose of this study was to (1) evaluate the differences in demographics of patients undergoing THA for DDH and primary OA; (2) evaluate differences in short-term perioperative and postoperative outcomes between the two groups via a propensity-matched pair analysis compiled from the National Surgical Quality Improvement Program (NSQIP) database; (3) evaluate procedural THA valuation between the two cohorts. We hypothesize that the two cohorts are different, therefore, necessitating added risk stratification for patients undergoing primary THA for hip dysplasia in bundled payment models.

Material and methods

All patients who underwent THA between 2008 and 2016 were identified from the American College of Surgeons NSQIP database via the common procedural test code for primary THA (27,130). These patients were then stratified based on diagnosis in two cohorts. The first cohort consisted of all patients who had an International Statistical Classification of Diseases and Related Health Problems 9 (ICD-9) code (715.XX) or ICD-10 code (M16.xx) for primary OA. The second cohort consisted of all patients who had DDH, which was defined as one of the following diagnosis codes: congenital hip dislocation (754.30 for ICD-9, Q65.XX for ICD-10), hip dysplasia (M16.XX, Q65.XX), or congenital pelvic malformation (Q74.2, Q89.8) (Table 1). Patients were given a diagnosis code that was either ICD-9 or ICD-10 without overlap, depending on the year of entry. Patients with a diagnosis of Legg-Calve-Perthes disease or slipped capital femoral epiphysis were not included in this analysis. The THA for primary OA cohort consisted of 115,166 patients, and the THA for DDH group consisted of 603 patients.

The nearest neighbor caliper is used for propensity matching to identify close pairs. A regression algorithm based on risk factors of interest is used to generate a propensity score for each subject [14]. Then the two groups (ostearthritis and DDH patients) are paired to the “nearest neighbor” by identifying an osteoarthritic patient with a propensity score within $1 \times 10^{-4}$ of the propensity score of a DDH patient to control for these confounders by making all other factors similar except for the diagnosis of OA versus DDH to try to isolate the independent contribution of DDH on risk of negative outcomes. The nearest neighbor matching caliper was set to $1 \times 10^{-4}$, and the algorithm matched patients on body mass index, gender, age, and diabetes mellitus. Five hundred fifty-seven matched pairs were identified from the data set and included in our analysis. Demographics of the two cohorts can be seen in Appendix I.

All patients were assessed for variability in operative time, length of stay (LOS), and postoperative complications. Outcomes of interest collected in the NSQIP database are assessed for 30 days from the date of surgery. Outcomes for this study included operating room (OR) time, procedural relative value units (RVUs), hospital LOS, death within 30 days, pulmonary complications, cardiac complications, surgical site infection, blood loss requiring postoperative transfusion, sepsis, discharge disposition, readmission, and reoperation.

Statistical analyses were performed using Stata, version 14.2 (StataCorp, College Station, TX). Continuous variables were assessed via $t$-test or Mann-Whitney U test when appropriate. Categorical variables were assessed via chi-squared or Fischer’s exact test, when appropriate.

Table 1

| Diagnosis code | Primary THA for developmental dysplasia of hip codes | N = 603 |
|----------------|---------------------------------------------------|---------|
| ICD-9          | 754.30 (Congenital hip dislocation)               | 52      |
|                | 755.63 (Other congenital deformity of hip joint)  | 274     |
| ICD-10         | M16.3 (unilateral OA from hip dysplasia)          | 9       |
|                | M16.30 (unilateral OA from hip dysplasia)         | 4       |
|                | M16.31 (right hip OA from hip dysplasia)          | 107     |
|                | M16.32 (left hip OA from hip dysplasia)           | 73      |
|                | Q65.01 (Right hip congenital dislocation)         | 2       |
|                | Q65.02 (Left hip congenital dislocation)          | 1       |
|                | Q65.1 (Bilateral hip congenital dislocation)      | 1       |
|                | Q65.30 (congenital partial hip dislocation)       | 1       |
|                | Q65.6 (congenital unstable hip)                   | 1       |
|                | Q65.8 (other congenital deformities of hip)       | 6       |
|                | Q65.89 (other specified congenital hip deformities) | 67     |
|                | Q65.9 (unspecified congenital hip deformity)      | 3       |
|                | Q74.2 (Other congenital malformation of pelvic girdle) | 1         |
|                | Q89.8 (Other specified congenital malformation)   | 1       |

Results

Patients in the DDH cohort were younger, women, and had fewer medical comorbidities, except smoking status, compared with the primary OA cohort (Table 2). After propensity-matched scoring, the OR time was 95.9 (±39) minutes for the primary OA group and 120.3 (±61.8) minutes for the DDH group, which was statistically significant ($P < .001$). The DDH cohort had a statistically significant higher rate of blood loss requiring postoperative transfusion than the primary OA cohort (12% vs 6.6%, $P = .002$). Hospital LOS was 2.5 (±1.2) days for the primary OA group and 2.8 (±1.8) days for the DDH group ($P < .001$). There were no other statistically significant differences between the primary OA group and DDH groups with respect to death ($P = .317$), cardiac complications ($P = .316$), sepsis ($P = .316$), or discharge disposition ($P = .123$). There was no identifiable difference in work RVU between the cohorts (211.1 ± 0.5, $P = .769$). No pulmonary complications of surgical site infections occurred in the matched cohort. There were 15 (2.9%) readmissions in the primary OA group and 18 (3.4%) in the DDH cohort ($P = .615$). There were 9 (1.7%) reoperations in the primary OA group and 13 (2.4%) in the DDH group ($P = .404$) (Table 2).

A multivariate regression model controlling for gender, body mass index, age, race, anesthesia type, preoperative functional
status. American Society of Anesthesiologists score, diabetes, hypertension, smoking, steroid use, chronic obstructive pulmonary disease, dialysis, history of cancer, and preoperative lab values (hematocrit, creatinine, albumin, platelets, bilirubin) demonstrated similar results except transfusion rate with regard to the outcomes of interest between the OA and DDH groups. (Table 4).

**Discussion**

As alternative payment models continue to evolve, there is a continued need to evaluate different indications to optimize bundles [1]. As evidenced by the differences in complication rates of THA for femoral neck fractures compared with primary OA [16], different indications for THA have different risk profiles [2,3]. Therefore, we sought to evaluate DDH, one of the leading causes of OA, to determine whether additional risk stratification is appropriate for this group of THA patients. In this study, we found that patients undergoing THA for DDH were younger, a greater proportion were women, and had fewer comorbidities. After controlling for these variables with propensity-matched regression, the only statistically significant differences were longer operative times, higher transfusion rates, and longer, though clinically insignificantly different, LOS.

Our findings that patients with DDH undergoing THA were significantly younger and healthier than those with primary OA (49.6 vs 65.3 years) is consistent with previously reported literature [5]. As other studies have reported [17,18], we found that female sex and ethnicity were also associated with patients undergoing THA for DDH. There are several risk factors for DDH that we were unable to assess because of availability in the database including breech presentation at birth, family history, first or postdate babies [18,19].

The authors believe that the variety of pathomorphologies seen in DDH and possibility for previous hardware owing to periacetabular osteotomies or proximal femoral osteotomies may be responsible for the longer operative times. Studies have shown a linear relationship between longer operative times with higher risk of readmissions, reoperations, surgical site infections, wound dehiscence, renal or systemic complications, and allogenic blood transfusions [20-22]. In a multivariable analysis of 99,444 patients who underwent TJA, Duchman et al. [21] found that overall complications were increased in patients with operative times greater than 120 minutes (5.9%) as compared with patients with operative times less than 60 minutes or 60 to 120 minutes (4.6%, 4.8%, respectively). In addition, each 30-minute increase in operative time beyond 120 minutes further increased risk [21]. Our study also found higher rates of transfusion rates in the DDH cohort. This is concerning as higher allogeneic blood transfusion after arthroplasty have been associated with higher odds of mortality and increased superficial and deep wound infections [23,24].

Although readmissions, reoperations, and systemic sepsis did not meet statistical significance, the higher rates in the DDH group, albeit small, may still be clinically relevant. In addition, the risks associated with severe DDH are underestimated by the findings of this study, as severe and mild DDH could not be stratified. It is presumable that patients with severe DDH would have longer

**Table 2**

Overall demographics of osteoarthritis and developmental dysplasia of hip disease.

| Demographics | Osteoarthritis (n = 115,166) | DDH (n = 603) | P-value |
|--------------|------------------------------|---------------|---------|
| Age (y)      |                              |               | <.001***|
| <70 y        | 73,699 (64.0%)               | 574 (95.2%)   |         |
| >70 y        | 41,467 (36.0%)               | 29 (4.8%)     |         |
| Gender       |                              |               | <.001***|
| Male         | 51,482 (40.7%)               | 160 (26.5%)   |         |
| Female       | 63,618 (55.3%)               | 443 (73.5%)   |         |
| Ethnicity    |                              |               | <.001***|
| White        | 91,826 (90.0%)               | 426 (68.9%)   |         |
| Black        | 7998 (7.8%)                  | 420 (68.2%)   |         |
| Hispanic     | 1452 (1.4%)                  | 52 (8.3%)     |         |
| Hawaiian     | 293 (0.3%)                   | 1 (0.2%)      |         |
| American Indian | 409 (0.4%)            | 5 (1.0%)      |         |
| Functional status |                         |               | <.001***|
| Independent  | 112,466 (98.0%)              | 586 (97.3%)   |         |
| Partially dependent | 2206 (1.9%)             | 13 (2.2%)     |         |
| Totally dependent | 81 (0.1%)              | 3 (0.5%)      |         |
| ASA class    |                              |               | <.001***|
| I-II         | 67,682 (58.8%)               | 452 (75.0%)   |         |
| III-IV       | 47,483 (41.2%)               | 151 (25.0%)   |         |
| Comorbidities|                              |               |         |
| Obesity (BMI>30 kg/m²) | 53,984 (46.9%) | 239 (39.6%)   | <.001***|
| Diabetes     | 13,300 (11.6%)               | 30 (5.0%)     | <.001***|
| Hypertension | 65,729 (57.1%)               | 180 (29.9%)   | <.001***|
| Smoker       | 14,037 (12.2%)               | 98 (16.3%)    | <.001***|
| COPD         | 4310 (3.7%)                  | 10 (1.7%)     | <.001***|
| Chronic steroids | 3483 (3.0%)            | 14 (2.3%)     | .315    |
| Dialysis     | 209 (0.2%)                   | 0 (0.0%)      | .295    |
| Cancer       | 183 (0.2%)                   | 0 (0.0%)      | .327    |
| Baseline low HCT (<30 g/dL) | 856 (0.8%)             | 3 (0.5%)      | .488    |
| Baseline renal insufficiency (Cr ≥ 2 mg/dL) | 7515 (6.7%)  | 49 (8.4%)     | .104    |
| Baseline low albumin (<1.5 g/dL) | 2038 (3.6%) | 10 (3.8%)     | .840    |
| Baseline low platelets | 626 (0.5%)             | 1 (0.2%)      | .207    |
| (≤100 billion cell/L) | 61,474 (53.4%) | 365 (60.5%)   | <.001***|
| General anesthetics | 60,076 (52.2%) | 313 (52.2%) | .982    |

**Table 3**

Propensity analysis of outcomes within 30 days of THA for OA compared with DDH.

| Results               | Osteoarthritis (n = 557) | DDH (n = 557) | P-value |
|-----------------------|--------------------------|---------------|---------|
| OR time, min ±SD      | 95.9 ± 39.0              | 120.3 ± 61.8  | <.001***|
| Death, n (%)          | 1 (0.2%)                 | 0 (0.0%)      | .317    |
| Pulmonary, n (%)      | 0 (0.0%)                 | 0 (0.0%)      | N/A     |
| Cardiac, n (%)        | 3 (0.5%)                 | 1 (0.2%)      | .316    |
| Surgical site infection, n (%) | 0 (0.0%) | 0 (0.0%) | N/A     |
| Transfusions, n (%)   | 37 (6.6%)                | 67 (12.0%)    | .002***|
| Sepsis, n (%)         | 1 (0.2%)                 | 3 (0.5%)      | .316    |
| Hospital LOS, d ±SD   | 2.5 ± 1.4                | 2.8 ± 1.8     | <.001***|
| Discharge to home, n (%) | 469 (89.0%) | 455 (85.9%) | .123    |
| Readmission, n (%)    | 15 (2.9%)                | 18 (3.4%)     | .615    |
| Reoperations, n (%)   | 9 (1.7%)                 | 13 (2.4%)     | .404    |
| Procedural RVU, n ± SD | 21.1 ± 0.5               | 21.1 ± 0.5    | .769    |

SD, standard deviation; OR, operating room; LOS, length of stay; RVU, relative value unit; DDH, developmental dysplasia of hip; OA, osteoarthritis. *P-value for significance set at <.005 after Bonferroni correction for 10 outcomes.

**Table 4**

Multivariate logistic regression of propensity matches.

| Results               | OR             | 95% CI   | P-value |
|-----------------------|----------------|----------|---------|
| Complication (OA vs DDH) | N/A            | -        | -       |
| Death (within 30 d)   | N/A            | -        | -       |
| Surgical site infection | N/A            | -        | -       |
| Cardiac               | 0.33           | 0.03 to 3.20 | .306    |
| Pulmonary             | N/A            | -        | -       |
| Transfusions (DDH)    | 1.92           | 1.26 to 2.92 | .002***|
| Sepsis                | 3.01           | 0.31 to 29.03 | .306    |
| Reoperation (within 30 d) | 1.43           | 0.61 to 3.40 | .402    |
| Readmissions (within 30 d) | 1.20           | 0.59 to 2.39 | .615    |
| Discharge home        | 0.75           | 0.52 to 1.08 | .123    |

OR, odds ratio; CI, confidence interval. ***Statistical significant, P < .005.
operative times and more perioperative complications than patients with mild DDH, who would be more similar to patients with primary OA.

Value-based and bundled payment models should accommodate for higher cost and need for resources to provide a primary THA for patients with DDH, given the greater operative times, greater risk of transfusions, and clinically significant higher rates of complications. This is further alarming as our results demonstrate work RVU for both cohorts were identical (21.1 ± 0.5) because there is no separate code available to indicate THA complexity related to patients with DDH. Our findings support continued development of proper bundled payment risk stratification [4,25] and provide guidelines for health policy makers for RVU adjustment based on case complexities and increased risk [26].

Strengths of this study include the large number of patients used in the registry and the propensity-matched design to control for the differences in the population. However, this study has several limitations. First, this is a retrospective registry study that is highly dependent on the validity of the data collected. Other registry studies [27] that have higher volume of DDH patients may be due to more accurate mechanisms for identifying DDH diagnosis than NSQIP, which is a general surgical database and not specific to orthopedics. Second, as ICD-10 and CPT codes were used for identification, it was not possible to collect certain variables such as those with prior hardware, which may not have been coded in the NSQIP. These variables may be responsible for the increase in operative time seen with DDH. Third, there may be selection bias in our study because complex dysplasia cases are more likely to be performed by higher-volume and fellowship-trained surgeons. As surgeon volume and arthroplasty fellowship training are associated with lower complication rates, lower operative times, and improved outcomes [28–36], this would bias the dysplasia group to trend towards improved outcomes in comparison with the general OA cohort. Surgeon volume and fellowship training are not available via the NSQIP database which prevented stratification of this potential effect. Fourth, the study period includes both ICD-9 and ICD-10 coding designations, which may present confounding bias. However, we do not believe there to be a significant difference because there was no coding overlap that would warrant eliminating the patients from the ICD-9 or ICD-10 groupings. Finally, the main limitation of our study is the inability for the NSQIP database (based on ICD-9/ICD-10 coding) to designate dysplasia severity. While THA for mild dysplasia has shown to have good outcomes [37–39], patients with more severe dysplasia have greater rates of revision, nerve palsy, fracture, blood transfusion, infection, instability, and complications overall in comparison to THA cohorts as a whole [27,40–43]. Pooling mild and severe dysplasia groups likely underestimates the true risks associated with THA for severe dysplasia.

Conclusions

In summary, patients who underwent THA for DDH were younger with a greater proportion being women and generally healthier compared to patients with OA. When controlling for these variables via a propensity-matched analysis, we found that THA for DDH was associated with a nearly 30-minute longer operative time, higher rates of postoperative transfusion and statistically significant but clinically insignificant longer length of hospital stay (0.3 days). As these findings are likely manifestations of the different anatomic morphologies seen in the spectrum of DDH, the authors advocate for acknowledgment of potential intraoperative complexity, which should be identified through thorough preoperative planning. A formal cost analysis is needed to determine whether DDH and primary OA should be in the same bundle and valued with the same RVUs.

Conflict of interest

Wudbhav N. Shankar reports board member/committee appointments for Pediatric Orthopaedic Society of North America, Committee chair and royalties, financial or material support from Wolters Kluwer. Neil P. Sereh reports paid consultant for Zimmer, Smith and Nephew and Medacta and royalties, financial or material support from Elsevier.

References

[1] Siddiqi A, White PB, Mistry JB, et al. Effect of bundled payments and health care reform as alternative payment models in total joint arthroplasty: a clinical review. J Arthroplasty 2017;32(8):2590. https://doi.org/10.1016/j.arth.2017.03.027.
[2] Schroer WC, Diesfeld PJ, LeMarr AR, Morton DJ, Reedy ME. Hip fracture does not belong in the elective arthroplasty bundle: presentation, outcomes, and service utilization differences in fracture arthroplasty care. J Arthroplasty 2018;33(5):1556. https://doi.org/10.1016/j.arth.2018.02.091.
[3] Grace TR, Patterson JT, Tangtippahoonbanta J, Krogue JD, Vail TP, Ward DT. Hip fractures and the bundle: a cost analysis of patients undergoing hip arthroplasty for femoral neck fracture vs degenerative joint disease. J Arthroplasty 2018;33(6):1681. https://doi.org/10.1016/j.arth.2018.01.071.
[4] Courtney PM, Bohl DD, Lau EC, Ong KL, Jacobs JJ, Della Valle CJ. Risk adjustment is necessary in Medicare bundled payment models for total hip and knee arthroplasty. J Arthroplasty 2018;33(8):2369. https://doi.org/10.1016/j.arth.2018.02.095.
[5] Hortofaklidis G, Karachalous T, Stamos KG. Epidemiology, demographics, and natural history of congenital hip disease in adults. Orthopedics 2000;23(8):823. https://doi.org/10.3928/0147-7447-20000801-16.
[6] Greber EM, Pelt CE, Gilliland JM, Anderson MB, Erickson JA, Peters CL. Challenges in total hip arthroplasty in the setting of developmental dysplasia of the hip. J Arthroplasty 2017;32(9):538. https://doi.org/10.1016/j.arth.2017.02.024.
[7] Hortofaklidis G, Lampropoulou-Adamidou K. Lessons learned from study of congenital hip disease in adults. World J Orthop 2016;7(12):785. https://doi.org/10.5312/wjo.v7.i12.785.
[8] García-Cimbrelo E, Munuera L. Low-friction arthroplasty in severe acetabular dysplasia. J Arthroplasty 1993;8(5):459. https://doi.org/10.1016/0883-5403(93)90100-3.
[9] Chougle A, Hemmady MV, Hoddkinson JP. Long-term survival of the acetabular component after total hip arthroplasty with cement in patients with developmental dysplasia of the hip. J Bone Joint Surg Am 2006;88(1):71. https://doi.org/10.1016/j.bjsa.2006.04.024.
[10] Hampton BJ, Harris WH. Primary cementless acetabular components in hips with severe developmental dysplasia or total dislocation. J Bone Joint Surg Am 2006;88(7):1549. https://doi.org/10.2106/JBJS.E.00624.
[11] Suchart DH, Porter ML. The long-term results of Charnley low-friction arthroplasty in young patients who have congenital dislocation, degenerative osteoarthritis, or rheumatoid arthritis. J Bone Joint Surg Am 1997;79(11):1599. https://doi.org/10.2106/00004623-199711000-00001.
[12] Grappiolo G, Spotorno L, Burastero G. Evolution of surgical techniques for the treatment of angular and torsional deviation in DDH: 20 years experience. HIF Int 2007;17(55):S105. https://doi.org/10.5301/hif.2008.4200.
[13] Charnley J, Feagin JA. Low-friction arthroplasty in congenital subluxation of the hip. Clin Orthop Relat Res 1973;91:98. https://doi.org/10.1097/00003086-197303000-00015.
[14] Inacio MCS, Chen Y, Paxton EW, Namba RS, Charnley J. The association between operative time and short-term complications in total hip arthroplasty: an analysis of 89,802 cases. J Arthroplasty 2007;22(8):1209. https://doi.org/10.1016/j.arth.2006.08.021.
[15] Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt 2014;34(5):502. https://doi.org/10.1111/opo.12131.
[16] Charette RS, Sloan M, Lee GC. Not all hip arthroplasties are created equal. Bone Joint J 2019;101-B(6_Supple_B):84. https://doi.org/10.1302/0301-620X.101B6B.2018122712.
[17] Woodacre T, Ball T, Cox P. Epidemiology of developmental dysplasia of the hip within the UK: refining the risk factors. J Child Orthop 2016;10(6):633. https://doi.org/10.1007/s11832-016-0796-5.
[18] Hattori T, Inaba Y, Ichinohe S, et al. The epidemiology of developmental dysplasia of the hip in Japan: findings from a nationwide multi-center survey. J Orthop Sci 2017;22(1):121. https://doi.org/10.1007/s00776-016-0809-7.
[19] Crowe F, Mani VJ, Ranawat CS. Total hip replacement in congenital dislocation and dysplasia of the hip. J Bone Joint Surg Am 1979;61(1):15. https://doi.org/10.2106/00004623-197961010-00004.
[20] Surace P, Sultan AA, George J, et al. The association between operative time and short-term complications in total hip arthroplasty: an analysis of 89,802
Laucis NC, Chowdhury M, Dasgupta A, Bhattacharyya T. Trend toward high-volume hospitals and the inpatient outcome in total knee arthroplasty: a systematic review of the literature. BMC Musculoskelet Disord 2012;13:250. https://doi.org/10.1186/1471-2474-13-250.

Cossec C Le, Colas S, Zureik M. Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France. Arthroplast Today 2017;3(3):176. https://doi.org/10.1016/j.artd.2017.03.010.

Ravi B, Jenkinson R, Austin PC, et al. Relation between surgeon volume and risk of complications after total hip arthroplasty: propensity score matched cohort study. BMJ 2014;348:g3284. https://doi.org/10.1136/bmj.g3284.

Murphy WS, Cheng T, Lin B, Terry D, Murphy SB. Higher volume surgeons have lower Medicare payments, readmissions, and mortality after THA. Clin Orthop Relat Res 2019;477(2):334. https://doi.org/10.1097/CORR.0000000000000370.

Kreder HJ, Deyo RA, Koepsell T, Swiontkowski MF, Kreuter W. Relationship between the volume of total hip replacements performed by providers and the rates of postoperative complications in the State of Washington. J Bone Joint Surg Am 1997;79(4):485. https://doi.org/10.2106/00004623-199704000-00003.

Katz JN, Losina E, Barrett J, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am 2001;83(11):1622. https://doi.org/10.2106/00004623-200111000-00002.

Ames JR, Lurie JD, Tomek IM, Zhou W, Koval KJ. Does surgeon volume for total hip arthroplasty affect outcomes after hemiarthroplasty for femoral neck fracture? Am J Orthop (Belle Mead NJ) 2010;39(8):E84.

Swaroop I, Marshall AC, Lee YY, Figgie MP. Implant survival and patient-reported outcomes after total hip arthroplasty in young patients with developmental dysplasia of the hip. Hip Int 2016;26(4):367. https://doi.org/10.5301/hipint.5000354.

Faldini C, Miscione MT, Chehrazzan M, et al. Congenital hip dysplasia treated by total hip arthroplasty using cementless tapered stem in patients younger than 50 years old: results after 12-years follow-up. J Orthop Traumatol 2011;12(4):213. https://doi.org/10.1007/s10195-011-0170-z.

Zhen P, Liu J, Chen H, Li X, Zhou S. Developmental hip dysplasia treated by total hip arthroplasty using a cementless Wagner cone stem in young adult patients with a small physique. BMC Musculoskelet Disord 2017;18(1):192. https://doi.org/10.1186/s12891-017-1554-9.

Sanchez-Sotelo J, Berry DJ, Trousdale RT, Cabanela ME. Surgical treatment of developmental dysplasia of the hip in adults: I. Arthroplasty options. J Am Acad Orthop Surg 2002;10(5):334. https://doi.org/10.5435/00124635-200209000-00005.

Thillemann TM, Pedersen AB, Johnsen SP, Seballe K. Implant survival after primary total hip arthroplasty due to childhood hip disorders: results from the Danish Hip Arthroplasty Registry. Acta Orthop 2008;79(6):769. https://doi.org/10.1080/174536708019016830.

Hartofilakis G, Karachalios T. Total hip arthroplasty for congenital hip disease. J Bone Joint Surg Am 2004;86(2):242. https://doi.org/10.2106/00004623-200402000-00005.

Yang S, Guo Q. Total hip arthroplasty in developmental dysplasia of the hip: review of anatomy, techniques and outcomes. World J Orthop 2012;3(5):42. https://doi.org/10.5312/wjo.v3.i5.42.
## Appendix Table 1
Demographics of the propensity matched pair.

| Demographics                        | Osteoarthritis (n = 557) | DDH (n = 557) | P-value |
|-------------------------------------|--------------------------|---------------|---------|
| Age, y ±SD                          | 51.1 ± 11.6              | 51.2 ± 11.6   | .908    |
| BMI (kg/m²)                         | 29.4 ± 6.5               | 29.6 ± 7.0    | .289    |
| Gender                              |                          |               | .549    |
| Male                                | 161 (28.9%)              | 152 (27.3%)   |         |
| Female                              | 396 (71.1%)              | 405 (72.7%)   |         |
| Ethnicity                           |                          |               | .969    |
| White                               | 408 (82.9%)              | 392 (89.1%)   |         |
| Black                               | 68 (13.8%)               | 19 (4.3%)     |         |
| Hispanic                            | 11 (2.2%)                | 23 (5.2%)     |         |
| Hawaiian                            | 2 (0.4%)                 | 1 (0.2%)      |         |
| American Indian                     | 3 (0.6%)                 | 5 (1.1%)      |         |
| Functional status                   |                          |               | .484    |
| Independent                         | 546 (98.2%)              | 541 (97.3%)   |         |
| Partially dependent                 | 9 (1.6%)                 | 12 (2.2%)     |         |
| Totally dependent                   | 1 (0.2%)                 | 3 (0.5%)      |         |
| ASA class                           |                          |               | .180    |
| I-II                                | 393 (70.6%)              | 413 (74.2%)   |         |
| III-IV                              | 164 (29.4%)              | 144 (25.8%)   |         |
| Comorbidities                       |                          |               |         |
| Obesity (BMI>30 kg/m²)              | 232 (41.7%)              | 225 (40.4%)   | .670    |
| Diabetest                           | 33 (5.9%)                | 30 (5.4%)     | .697    |
| Hypertension                        | 177 (31.8%)              | 176 (31.6%)   | .949    |
| Smoker                              | 136 (24.4%)              | 89 (16.0%)    | >.999   |
| COPD                                | 21 (3.8%)                | 10 (1.8%)     | .450    |
| Chronic steroids                    | 14 (2.5%)                | 14 (2.5%)     | >.999   |
| Dialysis                            | 0 (0.0%)                 | 0 (0.0%)      | N/A     |
| Cancer                              | 0 (0.0%)                 | 0 (0.0%)      | N/A     |
| Baseline low HCT (<30)              | 7 (1.3%)                 | 3 (0.6%)      | .207    |
| Baseline renal insufficiency (Cr ≥ 2 mg/dL) | 49 (9.0%)              | 45 (8.3%)     | .686    |
| Baseline low albumin (<3.5 g/dL)    | 11 (4.2%)                | 10 (4.0%)     | .925    |
| Baseline low platelets (<100 billion cells/L) | 2 (0.4%)                | 1 (0.2%)      | .563    |
| Baseline high bilirubin (≥ 2 mg/dL) | 309 (55.5%)              | 333 (59.8%)   | .146    |
| General anesthetics                 | 303 (54.6%)              | 285 (51.4%)   | .293    |

SD, standard deviation; COPD, chronic obstructive pulmonary disease; ASA, anesthesia physical classification; BMI, body mass index; HCT, hematocrit; DDH, developmental dysplasia of hip.